Introduction:The therapeutic scheme of triclabendazole (TCBZ), the recommended anthelmintic against Fasciola hepatica, involves 10mg/kg of body weight administered in a single dose; however, clinical trials in children are scarce. We evaluated the effi cacy and tolerability of 2 schemes of TCBZ. Methods: Eighty-four Peruvian children with F. hepatica eggs in their stools were allocated into 2 groups: 44 received 2 dosages of 7.5mg/kg each with a 12-h interval (Group I), and 40 received a single 10-mg/kg dose (Group II). Evaluation of effi cacy was based on the presence of eggs in stools, and tolerability was based on the presence of symptoms and signs post-treatment. Results: A parasitological cure was obtained in 100% of individuals from Group I and 95% of individuals from Group II. The most common adverse event was biliary colic. Conclusions: The tested scheme was effi cacious and tolerable, and it might be an optimal scheme in the region. To the best of our knowledge, this represents the largest series of children treated with TCBZ in a non-hospital setting.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.